Burkhart Erin
Known title: SVP, ControllershipCIK: 0001927648
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.
Transaction History
| GILD | ▲ Buy | Option Exercise | 2,223 | — | 9/22/2026 | View on chart |
| GILD | ▼ Sell | Tax Withholding | 768 | $117K | 9/22/2026 | View on chart |
| BMRN | ▼ Sell | Open Market | 1,786 | $106K | 5/20/2025 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 996 | $59K | 5/19/2025 | View on chart |
| BMRN | ▼ Sell | Open Market | 1,295 | $93K | 3/19/2025 | View on chart |
| BMRN | ▲ Buy | Grant | 5,970 | $0 | 3/17/2025 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 823 | $57K | 3/14/2025 | View on chart |
| BMRN | ▼ Sell | Open Market | 1,344 | $92K | 2/24/2025 | View on chart |
| BMRN | ▼ Sell | Open Market | 714 | $64K | 8/13/2024 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 993 | $76K | 5/17/2024 | View on chart |
| BMRN | ▼ Sell | Open Market | 2,286 | $206K | 4/10/2024 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 372 | $31K | 3/18/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 4,720 | $0 | 3/15/2024 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 796 | $73K | 5/16/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 3,760 | $0 | 3/15/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 11,130 | $0 | 5/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers
Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers. Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.